Phase 1/2 Trial: Targeting Resistance With SX-682 And Apalutamide or Enzalutamide
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase 1 Trial for DR-0202 Bispecific Antibody for Solid Tumors
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxBRL-302 Phase 1: A New CAR-T Cells Therapy for mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial: PMR-116, Targeting The Undruggable MYC Oncogene
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxUPDATE: OncoACP3 Moving to Phase 1 Trial as Therapeutic Agent
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxSn-117m-DTPA Emerges as Theranostic: Phase 1/2 Trials
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase 1 Trial of XL309: USP1 Inhibitor Targeting DNA Repair in Solid Tumors
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxUPDATE About ACE-232: Phase 1 Trial of a Novel CYP11A1 Inhibitor for mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxAMPLITUDE Trial Update: Niraparib Plus Abiraterone Shows Promise for HRR-Altered Metastatic Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare alphafold antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus personalized medicine Pluvicto prostate cancer PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- Phase 1/2 Trial for DS-3939a: A Novel TA-MUC1–Directed ADC for Advanced Prostate Cancer and Beyond July 29, 2025
- AI Platform Aims to Revolutionize Cancer Immunotherapy July 28, 2025
- FDA Clears First-in-Human Phase 1 Trial: RV-01 Targeting Solid Tumors July 28, 2025
- Phase 1 Trial For BL-M14D1 For Neuroendocrine Cancers July 28, 2025